Downloads
Abstract
The diagnosis and classification of lung cancer histology often face to many difficulties in pathological practice, especially on small core biopsies. Therefore, there is a need the immunohistochemistry for determining the exact types of histopathology, reflecting prognosis and indications for treatment of lung cancer.
Objective: Evaluation characteristics histological of lung cancer. Applying the revealing of immunohistochemistry to classify the lung cancer.
Matherial and Method: Through a study on 124 patients were diagnosed as lung cancer at Hue Central Hospital from June, 2016 to June, 2019. Prospective, descriptive, cross- sectional study.
Results: - Ratio Male: Female: 2,45 / 1. The average age is disease 54,16 ± 12, the lowest age: 17, maximum: 77. The highest group is 50-69 years old (58,07%). The two most common types of histology are adenocarcinoma (46.77%), squamous cell carcinoma (30.65%), Small cell mesothelioma accounts for a very low rate (5.65%).
- On the expression of immunohistochemistrical markers in adenocarcinoma: CK7 (+): 98.28%; TTF1 (+): 96.55%; CK5 / 6 (-): 100%, in squamous cell carcinoma: CK5 / 6 (+): 92.11%. P63 (+): 52.63%, TTF1 (-): 100%.
Conclusion: The expression of immunohistochemistrical markers such as CK7, TTF1, CK 5/6, P63 distinguishes between the gland cells and squamous cell, while immunohistochemistrical markers such as TTF1, NSE, Synaptophysin, Chromogranin to identify small cell carcinoma of the lung are very useful in diagnosing, classifying and treating the lung cancer.
References
Nguyễn Văn Bằng (2016). “Mô bệnh học ung thư phổi không tế bào nhỏ ở bệnh viện TW Huế”. Tạp chí ung thư học Việt Nam - Số 3 (2017), tr. 101-105.
Trần Văn Chương (2015). Nghiên cứu mô bệnh học ung thư phổi có ứng dụng phân loại IASLA/ ATS/ERS 2011 cho các mảnh sinh thiết phổi. Luận văn Thạc sỹ Y học, Đại học Y Hà Nội.
Phạm Nguyên Cường (2015). Nghiên cứu phân loại mô bệnh học ung thư biểu mô phổi theo WHO 2004 và IASLA/ATS/ERS 2011 có sử dụng dấu ẩn hóa mô miễn dịch. Luận án Tiến sỹ Y học, Đại học Y Hà Nội.
Nguyễn Mạnh Hùng (2016). “Nghiên cứu phân týp mô bệnh học và đột biến gene EGFR trên sinh thiết chẩn đoán ung thư phổi tại bệnh viện Quân y 103”. Tạp chý y học lâm sàng, Bệnh viện TW Huế, 37, tr.68 - 74.
Barletta JA, Perner S, Iafrate AJ, Yeap BY, et al (2009). “Clinical significance of TTF-1 protein and TTF-1 gen amplication in lung adenocarcinoma”. J Cell Mol Med. 13(8), 1977-1986.
GLOBOCAN, IARC (International Agency for Research on Cancer) (2018). Estimates of worldwide cancer 2018.
Kargi A, Gurel D, Tuna B (2007). “The diag- nostic value of TTF-1, CK 5/6, and p63 immu- nostaining in classification of lung carcinomas”. Appl Immunohistochem Mol Morphol. Dec, 15(4), 415-20.
Savic S., Sterlacci W., Schmid T. et al (2012), “tissue sraring application of the newwly pro- posed IASLA/ATS/ERS classification of adeno- carcinoma of the lung shows practical diagnos- tic and prognostic impact”, Am J Clin Pathol, 137(6), pp.946-956.
William D. Travis, MD, Elisabeth Brambilla, MD, Andrew G. Nicholson, MD,Yasushi Yatabe, MD, et al. (2015). “The 2015 World Health Or- ganization Classification of Lung Tumors”. State of the Art: Concise Reviw, pp. 1243-1260.
| Published | 02-12-2020 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 66 (2020) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2020.66.4 | |
| Keywords | ung thư phổi, typ mô bệnh học, hóa mô miễn dịch |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital